Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.32 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | CPT1A | P50416 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | GALR3 | O60755 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8055941 | 0.98 | MAPT (0.39) | MAPTSLC22A16MEN1CYP2C19RECQL | |
| SCHEMBL1057053 | 0.98 | MAPT (0.39) | MAPTSLC22A16MEN1CYP2C19RECQL | |
| Iodide SCHEMBL608287 | 0.84 | MAPT (0.35) | MAPTSLC22A16MEN1CYP2C19KMT2A | |
| SCHEMBL1902716 | 0.82 | MAPT (0.36) | MAPTSLC22A16MEN1CYP2C19KMT2A | |
| SCHEMBL570499 | 0.82 | MAPT (0.36) | MAPTSLC22A16MEN1CYP2C19KMT2A | |
| Hydrochloric Acid SCHEMBL5450059 | 0.80 | MAPT (0.39) | MAPTSLC22A16MEN1CYP2C19KMT2A | |
| Hydrochloric Acid SCHEMBL8827832 | 0.80 | MAPT (0.39) | MAPTSLC22A16MEN1CYP2C19KMT2A | |
| Iodide SCHEMBL400576 | 0.78 | MAPT (0.40) | MAPTSLC22A16MEN1CYP2C19KMT2A | |
| SCHEMBL6153646 | 0.76 | MAPT (0.41) | MAPTSLC22A16MEN1CYP2C19KMT2A | |
| SCHEMBL77665 | 0.76 | MAPT (0.41) | MAPTSLC22A16MEN1CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250033015-A1 | POLYDISULFIDE CORE-SHELL MICROCAPSULES | FIRMENICH SA (CH) | 2025-01-30 | — | — | US | disclosed |
| EP-4448159-A1 | POLYDISULFIDE CORE-SHELL MICROCAPSULES | Firmenich SA (CH) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023111039-A1 | POLYDISULFIDE CORE-SHELL MICROCAPSULES | FIRMENICH SA (CH) | 2023-06-22 | — | — | WO | disclosed |
| CN-111566081-B | Bisamide compound and preparation method and application thereof | 天津安百胜医疗科技有限公司 | 2021-04-06 | — | — | CN | disclosed |
| CN-111566081-A | Bisamide compound and preparation method and application thereof | 江苏达骏生物科技有限公司 | 2020-08-21 | — | — | CN | disclosed |
| US-20130071394-A1 | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use | PHARMATHENE, INC. | 2013-03-21 | — | — | US | disclosed |
| WO-2013040501-A1 | COMPOSITIONS AND COMBINATIONS OF ORGANOPHOSPHORUS BIOSCAVENGERS AND HYALURONAN-DEGRADING ENZYMES, AND USES THEREOF | PHARMATHENE, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| EP-1283902-A4 | ASSAY FOR DETECTING, MEASURING AND MONITORING THE ACTIVITIES AND CONCENTRATIONS OF PROTEINS AND METHODS OF USE THEREOF | US ARMY MEDICAL RES AND MATERI (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20040152145-A1 | Assay for detecting, measuring and monitoring the activities and concentrations of proteins and methods of use thereof | FEASTER SHAWN R (US) | 2004-08-05 | — | — | US | disclosed |
| US-6746850-B2 | ADDING PLURALITY OF SUBSTRATES TO PLURALITY OF ALIQUOTS OF TEST SAMPLE, MEASURING REACTION RATES BETWEEN PROTEIN AND EACH SUBSTRATE, DETERMINING ACTIVITY OR CONCENTRATION OF PROTEIN IN TEST SAMPLE USING PREDETERMINED SENSITIVITY COEFFICIENT | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2004-06-08 | — | — | US | disclosed |
| EP-1283902-A1 | ASSAY FOR DETECTING, MEASURING AND MONITORING THE ACTIVITIES AND CONCENTRATIONS OF PROTEINS AND METHODS OF USE THEREOF | United States Army Medical Research and Material Command (US) | 2003-02-19 | — | — | EP | disclosed |
| US-20020165620-A1 | Assay for detecting, measuring and monitoring the activities and concentrations of proteins and methods of use thereof | ARMY, UNITED STATES | 2002-11-07 | — | — | US | disclosed |
| WO-2001085985-A1 | ASSAY FOR DETECTING, MEASURING AND MONITORING THE ACTIVITIES AND CONCENTRATIONS OF PROTEINS AND METHODS OF USE THEREOF | UNITED STATES ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071394-A1 | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use | ACHE, BCHE, ENGASE | CHRM1 1403/4885CHRM3 298/4885MAPT 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.